IBB News and Press, iShares Biotechnology ETF From 01/17/24

2024-01-17 23:22:58 ET Summary The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to adjust drug prices in line with inflation, provid...

2024-01-17 11:38:06 ET More on Health Care Select Sector SPDR: XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech T...

2024-01-16 04:50:00 ET Summary Why US banks could be poised for a rebound? Sectors primed for a pivot if the Fed cuts. The outlook for healthcare and real estate. The potential for interest rate cuts this year by the U.S. Federal Reserve is raising the outlook for ...

2024-01-15 12:40:00 ET Summary All decisions around investing, everything we're seeing everyone doing is now colored by the rate situation. Artificial intelligence is a constantly growing and transforming phenomenon. Unlike artificial intelligence, a lot of the most exciting a...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-12 11:27:00 ET Summary Horiba is likely undervalued due to it being under followed, and offers a rare combination of a quality business at an attractive price. The company has high market share in specialized devices in various industries, including automotive, process &am...

2024-01-12 04:03:30 ET Summary December 2023 saw a surplus of $275 billion in the US private sector, driving aggregate demand and investment asset demand. Bank credit creation in December 2023 reached its highest level since December 2021, contributing $206 billion. The US sto...

2024-01-11 11:02:18 ET More on SPDR S&P 500 ETF Trust: Recession Forecasting - The Business Cycle Back To 1928 (Part 2) 2024 Analyst Outlook: Victor Dergunov On Undervalued Sectors Uncovering New Year Opportunities Why The SPY Is Falling (Technical Analysis) ...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...